Structure Therapeutics
Executive Summary
Structure Therapeutics is a dual-headquartered biotech (Shanghai/SF) leveraging structural biology expertise for GPCR drug discovery, with a standout oral GLP-1 program advancing to Phase II. Led by world-renowned structural biologist Raymond Stevens, the company operates through a Shanghai subsidiary but maintains clear BIOSECURE status. Strong pipeline positioning in the massive obesity/metabolic market with differentiated structural approach makes this an attractive partnership target for US pharma seeking innovative GPCR programs.
Structure: US-listed company (GPCR) with dual headquarters in Shanghai and San Francisco, operating drug discovery activities through Structure Therapeutics (Shanghai) subsidiary. The 10-K filing mentions VIE disclosures, suggesting potential Variable Interest Entity structures for China operations that will require careful due diligence review.
Key People
| Name | Title | Education | Flags |
|---|---|---|---|
Raymond Stevens | Co-Founder & Chairman | PhD, UC Berkeley; Professor at USC/Shanghai Tech |
Ownership & Shareholder Structure
Structure Therapeutics → Eli Lilly
Structure Therapeutics oral GLP-1 competes in Lilly's obesity market.
Subsidiaries & Affiliates(1)
| Entity | Type | Jurisdiction | Scope | Flags | BIOSECURE |
|---|---|---|---|---|---|
Structure Therapeutics (Shanghai) | operating | mainland china | GPCR-focused drug discovery using structural biology and AI. Lead: oral GLP-1 agonist. | NONE |
Corporate Events
Structure Therapeutics 10-K Annual Report
10-K annual report filed with SEC. Contains corporate structure, VIE disclosures, and risk factors.
Oral GLP-1 program advances to Phase II
Structure Therapeutics' oral GLP-1 receptor agonist advances. Competing in the massive obesity/metabolic market with differentiated structural biology approach.
Clinical Trials(7 total)
4
Phase 2
2
Phase 1
1
Phase 1, Phase 2
| NCT ID | Interventions | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07400588 | Aleniglipron, Placebo | Ph.2 | RECRUITING | 50 |
| NCT07169942 | aleniglipron or placebo | Ph.2 | ACTIVE NOT RECRUITING | 71 |
| NCT06703021 | aleniglipron or placebo, aleniglipron or placebo, aleniglipron or placebo, aleniglipron or placebo | Ph.2 | ACTIVE NOT RECRUITING | 82 |
| NCT06693843 | Aleniglipron or Placebo, Aleniglipron or Placebo, Aleniglipron or Placebo, Aleniglipron, Aleniglipron, Aleniglipron, Aleniglipron | Ph.2 | ACTIVE NOT RECRUITING | 220 |
| NCT06139055 | GSBR-1290 (Capsule/Tablet), GSBR-1290, Placebo, Placebo (Capsule/Tablet) | Ph.1 | UNKNOWN | 70 |
| NCT05893043 | GSBR-1290, Placebo | Ph.1 | COMPLETED | 18 |
| NCT05762471 | GSBR-1290, Placebo | Ph.1, Ph.2 | COMPLETED | 142 |
Top Publications (by citations)
Wnt/beta-catenin signaling: components, mechanisms, and diseases.
MacDonald BT, Tamai K, He X.
Molecular mechanisms and clinical applications of angiogenesis.
Carmeliet P, Jain RK.
Cellular and molecular mechanisms of pain.
Basbaum AI, Bautista DM, Scherrer G, Julius D.
Complement: a key system for immune surveillance and homeostasis.
Ricklin D, Hajishengallis G, Yang K, Lambris JD.
Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases.
Parada Venegas D, De la Fuente MK, Landskron G, González MJ, Quera R, Dijkstra G, Harmsen HJM, Faber KN, Hermoso MA.
Prostaglandins and inflammation.
Ricciotti E, FitzGerald GA.
High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor.
Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, Stevens RC.
Activation and regulation of the inflammasomes.
Latz E, Xiao TS, Stutz A.
Pro-resolving lipid mediators are leads for resolution physiology.
Serhan CN.
Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators.
Serhan CN, Chiang N, Van Dyke TE.
BIOSECURE Risk
Company has clear BIOSECURE status with no BCC designation, and drug discovery operations do not fall under restricted categories
Mitigation: No specific mitigation needed given clear status, but dual China-US structure requires ongoing monitoring of regulatory changes
BD Intelligence
Therapeutic Areas:
Recent Deals: No specific recent out-licensing deals mentioned, suggesting potential availability for partnerships
Approach: Approach with focus on oral GLP-1 program and broader GPCR platform. Strong scientific leadership and advancing clinical programs suggest high partnering potential.
Red Flags
- ⚠VIE structure complexity requiring detailed legal review
- ⚠Dual China-US operations may face future regulatory scrutiny despite current clear status
Quick Facts
- Key People
- 1
- Subsidiaries
- 1
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 2
- Gov-Connected
- 0
- Clinical Trials
- 7
- Publications
- 10
- Drug Molecules
- 0
- Relationships
- 1
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (7 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (10 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.